Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma

Fig. 2

CA916798 promotes growth of LUAD cells in vitro and in vivo

A) The efficiency of CA916798 knockdown in A549 and PC9 cells with three individual shRNA sequence targeting CA916798. shCA916798-1 and − 3 are used in A549 and PC9, respectively, for the following experiments

B) Growth curve of CA916798-knockdown LUAD cells and mock cells as measured by CCK8 assay. Data are shown as mean ± SD (n = 3; *P < 0.05, ***P < 0.001)

C) Colony formation of CA916798-knockdown LUAD cells and mock cells. Data are shown as mean ± SD (n = 3, *P < 0.05, ** P < 0.01)

D and E) Measurement on migration (D) and invasion (E) in CA916798-knockdown cells and mock cells. Data are shown as mean ± SD (n = 3)

F-H) Tumor image (F), tumor volume (G), and tumor weight (H) of xenograft models generated using A549-shCA916798 and mock cells. Data are shown as mean ± SD (n = 5, *P < 0.05)

I) HE and IHC staining of tumor tissues from experimental mice obtained 28 days after implantation

Back to article page